{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:06:54Z","timestamp":1783130814500,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.annonc.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T20:59:45Z","timestamp":1595365185000},"page":"1282-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment compliance in early-stage anal cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"A.","family":"Pretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Trevisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deleporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2020.07.006_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02586980","article-title":"Combined therapy for cancer of the anal canal: a preliminary report","volume":"17","author":"Nigro","year":"1974","journal-title":"Dis Colon Rectum"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2020.07.006_bib2","doi-asserted-by":"crossref","first-page":"iii10","DOI":"10.1093\/annonc\/mdu159","article-title":"Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2020.07.006_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00a0\u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2020.07.006_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Glynne-Jones","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2020.07.006_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2020.07.006_bib6","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2020.07.006_bib7","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.18632\/oncotarget.23545","article-title":"The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis","volume":"9","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"34","key":"10.1016\/j.annonc.2020.07.006_bib8","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"825","key":"10.1016\/j.annonc.2020.07.006_bib9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1259\/0007-1285-69-825-830","article-title":"The reduction of tumour control with increasing overall time: mathematical considerations","volume":"69","author":"Jones","year":"1996","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.annonc.2020.07.006_bib10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0360-3016(93)90371-2","article-title":"Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials","volume":"27","author":"Cox","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.annonc.2020.07.006_bib11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus. results of a post-hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2020.07.006_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2020.07.006_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1470-2045(00)00019-X","article-title":"Repopulation of tumour cells between cycles of chemotherapy: a neglected factor","volume":"1","author":"Davis","year":"2000","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.07.006_bib14","author":"ISRCTN registry"},{"issue":"5","key":"10.1016\/j.annonc.2020.07.006_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/clon.2002.0111","article-title":"Practical methods for compensating for missed treatment days in radiotherapy, with particular reference to head and neck schedules","volume":"14","author":"Dale","year":"2002","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"22","key":"10.1016\/j.annonc.2020.07.006_bib16","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1002\/cncr.31721","article-title":"Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: a National Cancer Data Base study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.07.006_bib17","author":"The Royal College of Radiologists"},{"issue":"8","key":"10.1016\/j.annonc.2020.07.006_bib19","first-page":"401","article-title":"The increasing incidence of anal cancer: can it be explained by trends in risk groups?","volume":"71","author":"Van der Zee","year":"2013","journal-title":"Neth J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420399415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420399415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:58:58Z","timestamp":1760335138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420399415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0923753420399415"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.07.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment compliance in early-stage anal cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.06.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}